ORCHID MESIAS: Open Payments
NPI 1710627880 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$370 in 10 payments from 9 companies in 2025. Trend: 2023 $561 · 2024 $511 · 2025 $370
Food & beverage: $370
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 1 | $121 |
| Globus Medical, Inc. | 1 | $69 |
| Lilly USA, LLC | 2 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $30 |
| Cranial Technologies, Inc | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
Products named: Ozempic, Senza, MOUNJARO, Kerendia, Doc Band, ROTATEQ, Belbuca, JARDIANCE.
Industry payments across MD — which companies pay providers there.
